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Garlic oilhasbeen reported toprotect the cardiovascularsystem;however,the eﬀectsandmechanismsbehind thecardioprotection
of garlic oil on diabetes-induced cardiaomyopathy are unclear. In this study, we used streptozotocin (STZ)-induced diabetic rats
to investigate whether garlic oil could protect the heart from diabetes-induced cardiomyopathy. Wistar STZ-induced diabetic rats
received garlic oil (0, 10, 50 or 100mgkg−1 body weight) by gastric gavage every 2 days for 16 days. Normal rats without diabetes
were used as control. Cardiac contractile dysfunction and cardiac pathologic hypertrophy responses were observed in diabetic
rat hearts. Cardiac function was examined using echocardiography. In addition to cardiac hypertrophy-related mitogen-activated
protein kinases (MAPK) pathways (e.g., p38, c-Jun N-terminal kinases (JNK) and extracellularly responsive kinase (ERK1/2)),
the IL-6/MEK5/ERK5 signaling pathway was greatly activated in the diabetic rat hearts, which contributes to the up-regulation
of cardiac pathologic hypertrophy markers including atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), and
leads to cardiac contractiledysfunction. Garlic oiltreatment signiﬁcantlyinhibited the up-regulation in MAPK(e.g.,p38,JNKand
ERK1/2) andIL-6/MEK5/ERK5 signalingpathwaysin thediabetic rathearts, reducing thelevels of cardiac pathologichypertrophy
markers such as ANP and BNP, and improving the cardiac contractile function. Collectively, data from these studies demonstrate
that garlic oil shows the potential cardioprotective eﬀects for protecting heart from diabetic cardiomyopathy.
1.Introduction
Diabetes mellitus (DM) is one of the major risk factors for
cardiovascular disease development, accounting for 80% of
alldiabeticmortality[1].Inaddition,themortalityofcardiac
disease in patients with diabetes is 2- to 4-fold higher than
that in subjects without diabetes [2]. The destruction of car-
diac function has been well documented in both clinical and
experimental diabetes [3–5]. Several pathological processes
may initiate myocyte injury and myocardial dysfunction in
patients with diabetes. Diabetic cardiomyopathy, character-
ized by cardiac hypertrophy and the presence of diastolic
and/or systolic contractile dysfunction, eventually leads to
heart failure [6].2 Evidence-Based Complementary and Alternative Medicine
Cardiac hypertrophy is deﬁned as an enlargement of the
heart with the increase in volume of cardiomyocyte cell.
Cardiac hypertrophy is a multi-step process that occurs in
response to various pathological stimuli such as myocardial
infarction (MI), hypertension, valvular insuﬃciency, infec-
tious agents and endocrine disorders [7, 8]. Under these
stimuli, hypertrophic growth of myocardium is required
to adapt to the increased work load of the heart and/or
preserve the heart pump function by increasing muscle mass
[8, 9]. Cardiac pathological hypertrophy is characterized
by an increase in cell size, sarcomere reorganization and
activation of the fetal genes including atrial natriuretic
peptide (ANP), B-type natriuretic peptide (BNP), β-myosin
heavy chain and skeletal alpha actin [10, 11]. Prolonged
hypertrophic status has been reported to be associated with
the decompensation of heart function, the development of
heart failure and suddendeath in humans [12–14]. Epidemi-
ological studies have showed that cardiac hypertrophy is an
independent risk factor for cardiac morbidity and mortality
[15, 16].
Cardiac hypertrophy response is typically induced by
active membrane-bound receptors that lead to the activation
of intracellular signaling pathways through multiple GTPase
proteins, kinases and phosphatases. A large number of stud-
ies have been dedicated to exploring the molecular mech-
anisms behind the hypertrophic response of myocardium
[17]. Mitogen-activated protein kinases (MAPKs) include
three major subfamilies such asthe extracellularly responsive
kinases (ERKs), the c-Jun N-terminal kinases (JNKs), also
known as stress-activated protein kinases (SAPKs), and the
p38 MAPKs [18]. In the heart, MAPK signaling pathways
have been reported to participate in the development
of cardiac hypertrophy in response to stimuli [10, 19,
20]. For example, depletion of ERK1/2 signaling pathway
using antisense oligodeoxynucleotides signiﬁcantly attenu-
ated phenylephrine (PE)-induced cardiomyocyte hypertro-
phy in culture [21]. MEK1 inhibitor U0126 greatly inhibited
both endothelin-1 (ET-1) and PE-induced cardiomyocyte
hypertrophy in vitro [22]. p38-MAPK was observed in
pressure overload [23, 24], and ET-1/PE stimulation [25],
and the increased p38-MAPK activity has been showed to
involve in many cardiovascular diseases such as hyperten-
sion, cardiac hypertrophy, myocardial ischemia and heart
failure [26]. In cardiomyocytes, the increased activity of
JNK is suﬃcient to induce cardiomyocyte hypertrophy in
response to mechanical stretching [27]o rh y p e r t r o p h i c
agonists such as ET-1 [28], PE [29] or angiotensin II (Ang
II) [30]. Down-regulation of JNK activity by dominant-
negative MKK4 mutant or MEKK1 disruption signiﬁcantly
reduced the hypertrophic response induced by ET-1 [28],
pressure overloading [31] and ischemia/reperfusion [32].
Elevated intracardiac interleukin-6 (IL-6) is reported and
causescardiachypertrophy throughtheIL-6signal transduc-
ing receptor component, glycoprotein 130 (gp130), which
eventually leads to heart failure (HF) [33]. The activated
MEK5/ERK5 signaling pathway by IL-6 family cytokines,
leukemia inhibitory factor (LIF) and carddiotrophin-1 (CT-
1) has been shown to result in the serial assembly of
sarcomeres and eccentric cardiac hypertrophy [34].
Garlic (Allium sativum) has played important dietary
and medicinal roles for centuries. Due to its exhibition of
inhibiting enzymes involved in lipid synthesis, decreasing
platelet aggregation, preventing lipid peroxidation of oxi-
dized erythrocytes and low-density lipoprotein, increasing
antioxidant status and inhibiting angiotension-converting
enzyme [35–38], today the medicinal use of garlic is
widespread and growing. The main property of garlic for
therapeutic eﬀects is as an eﬀective antioxidant against
oxidativedamageincardiovasculardiseases[39].Inaddition,
according to Ryan’s report [40], garlic is also the most
commonly used alternative medication by diabetic patients.
The antihyperglycemic eﬀect of garlic has been reported in
several studies [41–44]. It was also reported that garlic can
improve hyperglycemia in diabetic patients [45]. However,
information about the eﬀects of garlic on the diabetic heart
is very limited.
Therefore, we hypothesize that cardiac contractile dys-
functionandcardiacpathologichypertrophyinducedbydia-
betes can be alleviated by garlic oil supplement. The results
demonstrated that garlic oil treatment down-regulates activ-
ities of MAPKs (e.g., p38, JNK and ERK1/2) and IL-
6/MEK5/ERK5 signaling pathways, and reduces expressions
of pathologic hypertrophy response genes such as ANP
and BNP, which contributes to the improvement of cardiac
contractile function.
2.Methods
2.1. Garlic Oil Preparation. Garlic oil was prepared as
described [46]. Brieﬂy, a steam distillation technique was
used, and the ﬁnal product contained major garlic oil essen-
tial components, including diallyl disulﬁde, diallyl trisulﬁde,
diallyl sulﬁde and minor amounts of many other volatile
compounds.
2.2.AnimalModelandTreatments. MaleWistarrats(4weeks
old) were purchased from the National Animal Breeding
and Research Center (Taipei, Taiwan). The animals were
kept under a 12-h light-dark cycle and ambient temperature
was maintained at 25◦C. Animals were given free access
to water and standard laboratory chow (Lab Diet 5001;
PMI Nutrition International Inc., Brentwood, MO, USA).
Housing conditions and experimental procedures were per-
formed according to the NIH Guide for the Care and Use
of Laboratory Animals and all protocols were approved by
the Institutional Animal Care and Use Committee of Chung
Shan Medical University, Taichung, Taiwan. After 1 week
of acclimatization, diabetes was induced by injection of
streptozotocin(STZ,65mgkg−1 body weight (BW)in citrate
buﬀer, pH 4.5) into a lateral tail vein [47]. Control rats were
injected with the same volume of citrate buﬀer. After 3 days
of injection, animals in which diabetes had been successfully
induced were randomly separated into four groups and fed
10, 50 and 100mgkg−1 BW garlic oil or vehicle (corn oil,
2mlkg −1 BW) for 16 days. It was done by daily oral gavages
in the vehicle corn oil. The nondiabetic control animals were
fed corn oil (2mlkg−1 BW). After 16 days of treatment,
all animals were anesthetized and echocardiography wasEvidence-Based Complementary and Alternative Medicine 3
performed. Then, they were sacriﬁced and their hearts were
removed for further analysis.
2.3. In Vivo Cardiac Function. Transthoracic echocardio-
grams were performed at heart rates (HRs) of 300–450 beats
per minute in rats anesthetized with isoﬂurane mixed with
O2 at ﬂow rate of 5 psi before and 16 days after the garlic
oil feeding by an echo machine (Vivid i, 10S transducer, GE
M e d i c a lS y s t e m s ,M i l w a u k e e ,W I ,U S A )u s i n ga4 – 1 1M H z
phase-array transducer. M-mode images were obtained
in the parasternal long- and short-axis views of the left
ventricle. Left ventricular end-diastolic diameter (LVEDD),
left ventricular end-systolic diameter (LVESD) and posterior
wall thickness (PWT) were determined for ﬁve cardiac cycles
and averaged. The percentage of LV fractional shortening
(FS, %) was calculated as ((LVEDD – LVESD)/LVEDD) ×
100 (%). Left ventricular end diastolic volume (LVEDV)
and left ventricular end systolic volume (LVESV) were
used to calculate ejection fraction (EF, %) = ((LVEDV –
LVESV)/LVEDV) ×100(%).LVmass wascalculatedas1.855
×((LVEDD+PW+intraventricularseptalthickness(IVS))3
–(LVEDD))(mg) and cardiac output(CO)was calculatedas
stroke volume × HR (lmin−1).
2.4. Tissue Extraction. The left ventriclesamples were homo-
genized for protein extract in a PBS buﬀer (0.14M NaCl,
3mMK Cl,1.4mMKH 2PO4,1 4m MK 2HPO4)a tac o n c e n -
tration of 1mg tissue/10μl PBS for 5min. The homogenates
wereplacedonicefor10minandthencentrifugedat11000g
for 30min. The supernatant were collected and stored at
−70◦C for further analysis.
2.5. Protein Contents. The protein content of cardiac tissue
extract was analyzed using the Bradford protein assay [48]
using the protein-dye kit (Bio-Rad, Richmond, CA, USA).
A commercially available bovine serum albumin (Sigma
Chemical, St Louis, MO, USA) was used as a standard solu-
tion. Changes in optical density were monitored at 595nm.
2.6. Electrophoresis and Western Blot. SDS-PAGE was carried
out as described using 10% polyacrylamide gels. After
the electrophoresis of samples at 140V for 3.5h, the gels
were equilibrated for 15min in 25mM Tris-HCl, pH 8.3,
containing 192mM glycine and 20% (V/V) methanol.
Electrophoresed proteins were transferred to nitrocellulose
paper (Amersham, Hybond-C Extra Supported, 0.45 Micro)
using a Hoefer Scientiﬁc Instruments Transphor Units at
100mA for 14 h. Nitrocellulose papers were incubated
for 2h in blocking buﬀer containing 100mM Tris-HCl,
pH7.5, 0.9% (w/v) NaCl, 0.1% (v/v) fetal bovine serum.
Monoclonal antibodies (Transduction Laboratories) were
diluted (1:1000) in buﬀer containing 100mM Tris-HCl,
pH 7.5, 0.9% (w/v) NaCl, 0.1% (v/v) Tween-20 and 1%
(v/v) fetal bovine serum. Incubations were performed for
3.5h. The immunoblots were washed three times in blotting
buﬀerfor 10min and then immersed in the second antibody
solution containing alkaline phosphatase goat anti-rabbit
immunoglobulin G (dilution 1:2000) (Promega) for 1h.
The ﬁlters were then washed three times in blotting buﬀer
for 10min. Color development was presented in a 20ml
mixture consisting of 7mg nitro blue tetrazolium, 5mg
5-bromo-4-chloro-3-indolyl-phosphate, 100mM NaCl and
5mMMgCl 2 in 100 mM Tris-HCl, pH 9.5. Signal intensity
was quantitated using a PhosphoImager. α-Tubulin was used
as a loading control.
2.7. Statistical Analysis. Statistical diﬀerenceswere examined
by one-way analysis of variance. P<. 05 was considered
statistically signiﬁcant. Data were expressed as mean ± SE.
3.Results
3.1. Improvement in Cardiac Contractile Dysfunction in
Diabetic Rats in Response to Garlic Oil Feeding. In order to
assess cardiac function and dimension in vivo, we performed
echocardiography on diabetic and normal control rats. In
addition to signiﬁcantly high blood glucose induced in
diabetic rats, all of the animals with or without STZ-induced
diabetes showed a normal appearance and had a normal
global cardiac structure and function at Day 0 of induction
(Table 1). After 16 days of induction, compared to control
group blood glucose increased much more higher and the
BW, HR and CO decreased in all diabetic animal groups.
T h ep e r c e n t a g eo fF Sa n dE F ,c a l c u l a t e df r o mt h eL V E D Do r
LVEDV and LVESD or LVESV, typically representing cardiac
contractile function in rat hearts were largely decreased in
diabetic rat hearts. Garlic oil supplement increased HR, CO,
FS% and EF% in a dose-dependent manner in diabetic
hearts. The BW and blood glucoseexhibited unchanged after
garlic oil treatment between the four groups of diabetic
rats. Figure 1 shows the echocardiologic M-mode of left
ventricular dimensions from rat hearts in both control and
diabeticratsfed withdiﬀerentdosesofgarlic oil.Collectively,
garlic oil attenuates the impaired cardiac contractility, and
decreased CO and HR in diabetic rat hearts.
The degree of cardiac hypertrophy in diabetic rats was
assessed using the ratio of left ventricle mass (LVM) to tibia
length (TL). Although the degree of hypertrophy was higher
in diabetic rats than in control rats, the ratio of LVM to TL
did not diﬀer between the four groups of diabetic rats.
3.2. The Activation of Cardiac Hypertrophy-related MAPKs
(p38, JNK and ERK1/2) in the Diabetic Rat Hearts was
Reduced by Garlic Oil Supplement. To further identify
which signal transduction pathway(s) was involved in
the mechanism behind diabetes-induced cardiac hypertro-
phy, we detected the phosphorylation/activation of cardiac
hypertrophy-related MAPKsincludingp38,JNKandERK1/2
in left ventricle from the diabetic rat hearts. We found that
phosphorylated p38 is signiﬁcantly increased by ∼5.74-fold;
phosphorylated JNK is signiﬁcantly increased by ∼4.32-fold;
phosphorylated ERK1/2 is signiﬁcantly increased by ∼5.03-
fold (Figure 2).Interestingly, the diabetes-induced activation
of MAPKs (e.g., p38, JNK and ERK1/2) in the diabetic rat
hearts was notably reduced by garlic oil supplement (10, 50
and 100mgkg−1 BW).
3.3. The Up-regulation of Intracardiac IL-6 Expression in the
Diabetic Rat Hearts was Reduced by Garlic Oil Supplement.
Overexpression of IL-6 in the myocardium in acute MI4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Representative echocardiographic M-mode images from at least four cardiac contractile cycles of control and diabetic rat hearts.
GO-0, -10, -50 and -100 represent the doses of 0, 10, 50 and 100mg garlic oil per kg BW.
(AMI) appears to be associated with the mechanism of
cardiachypertrophy[49].Theleftventriclesfromdiabeticrat
hearts showed a signiﬁcant protein level of IL-6, compared
to the control group (Figure 3). On supplementing garlic oil
(10, 50 and 100mgkg−1 BW) to the diabetic rats, we found
that intracardiac IL-6 expression was reduced in a dose-
dependent manner.
3.4. Garlic Oil Supplement Reduces Expression of MEK5 and
ERK5 in the Diabetic Rat Hearts. Activated MEK5/ERK5Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Detection of (a) phosphorylated p38, (b) phosphorylated JNK and (c) phosphorylated ERK1/2 protein levels from the left
ventricles in control and diabetic rats, analyzed by western blotting. GO-0, -10, -50 and -100 represent the doses of 0, 10, 50 and 100mg
garlic oil per kg BW. Signal intensity was quantitated using a PhosphoImager. Equal loading was assessed with an anti α-tubulin antibody.
Theaverageresult ±SEofthree independent experiments isshown. ∗P<. 05, ∗∗P<. 01represent signiﬁcantdiﬀerences from controlgroup.
signaling pathwayby IL-6family cytokineshas been reported
to lead to the development of eccentric cardiac hypertrophy
[34]. In this study, overexpression of MEK5 was detected
in the diabetic rat hearts (Figure 4). The downstream
ERK5 was also signiﬁcantly up-regulated in both protein
expression (Figure 5(a))a n dp r o t e i na c t i v a t i o n( Figure 5(b))
in the diabetic rat hearts. The results suggested that the
activated MEK5/ERK5 signaling pathway participates in the6 Evidence-Based Complementary and Alternative Medicine
Table 1: Physiologicaland echocardiographic parameters in rat hearts.
Control DM
GO-0 GO-10 GO-50 GO-100
At basal level
BW (g) 189.1 ± 14.4 153.0 ± 14.1∗ 138.5 ± 17.5∗ 165.0 ± 15.0∗ 154.5 ± 11.5∗
Blood glucose (mg dl−1) 73.8 ± 6.5 269.2 ± 59.8∗ 215.0 ± 42.3∗ 256.8 ± 44.5∗ 218.3 ± 49.5∗
HR (beats/min) 415.7 ± 10.5 400.0 ± 22.5 397.4 ± 29.0 418.8 ± 39.1 392.4 ± 21.3
LVEDD (mm) 5.70 ± 0.54 5.29 ± 0.38 6.10 ± 0.75 5.36 ± 0.43 6.07 ± 0.62
LVESD (mm) 2.60 ± 0.29 2.61 ± 0.03 2.95 ± 0.51 2.68 ± 0.29 3.11 ± 0.28
FS (%) 49.8 ± 2.0 48.6 ± 3.5 49.3 ± 4.0 48.0 ± 2.1 49.6 ± 3.9
EF (%) 87.6 ± 0.9 86.7 ± 2.9 86.7 ± 3.5 87.4 ± 1.3 85.6 ± 3.0
CO (l min−1)0 . 2 0 ± 0.05 0.19 ± 0.08 0.20 ± 0.06 0.19 ± 0.02 0.19 ± 0.01
LVM (mg) 13.22 ± 0.05 13.29 ± 0.01 13.55 ± 0.03 13.42 ± 0.02 13.50 ± 0.07
After 16-day feeding of diﬀerent doses of garlic oil
BW (g) 331.3 ± 10.5 225.0 ± 14.4∗ 155.0 ± 20.2∗ 202.5 ± 30.3∗ 212.5 ± 21.7∗
Blood glucose (mg dl−1) 96.0 ± 7.4 412.0 ± 12.7∗ 423.5 ± 7.8∗ 467.5 ± 19.3∗ 453.8 ± 18.3∗
HR (beats/min) 413.5 ± 1.4 279.0 ± 10.2∗ 323.0 ± 1.6∗ 364.5 ± 26.8# 439.7 ± 13.6#
LVEDD (mm) 6.65 ± 0.2 6.93 ± 0.23 7.70 ± 0.17∗ 7.45 ± 0.29 7.65 ± 0.29∗
LVESD (mm) 2.45 ± 0.14 4.60 ± 0.01∗ 4.65 ± 0.29∗ 4.15 ± 0.87∗,# 3.30 ± 0.58∗,#
FS (%) 62.6 ± 3.6 33.5 ± 2.3∗ 39.4 ± 0.8∗ 44.2 ± 0.9∗ 57.6 ± 1.3#
EF (%) 93.4 ± 1.7 68.0 ± 3.0∗ 75.6 ± 0.8∗ 80.5 ± 0.9∗,# 90.8 ± 0.8#
CO (l min−1)0 . 1 5 ± 0.66 0.13 ± 0.38 0.25 ± 0.17 0.23 ± 0.01 0.37 ± 0.03∗,#
LVM (mg) 13.27 ± 0.17 13.21 ± 0.04 13.21 ± 0.04 13.17 ± 0.01 13.16 ± 0.06
LVM/TL (mg mm−1) 0.329 ± 0.001 0.413 ± 0.009∗ 0.358 ± 0.019 0.343 ± 0.013# 0.323 ± 0.002#
Results are mean ± SEM.
∗P < .05 versus with control group. #P<. 05 versus with GO-0 group (n = 6 rats in each group).
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Figure 3: Detection of IL-6 protein levels from the left ventricles in
control and diabetic rats, analyzed by western blotting. GO-0, -10,
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Figure 4: Detection of MEK5 protein levels from the left ventricles
in control and diabetic rats, analyzed by western blotting. GO-0,
-10, -50 and -100 represent the doses of 0, 10, 50 and 100mg
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Figure 5: Detection of (a) ERK5 and (b) phosphorylated ERK5 protein levels from the left ventricles in control and diabetic rats, analyzed
by western blotting.GO-0,-10,-50and-100represent the dosesof0,10,50and100mggarlicoil per kgBW.Signalintensitywasquantitated
using a PhosphoImager. Equal loading was assessed with an anti α-tubulin antibody. The average result ± SE of three independent
experiments is shown. ∗∗P<. 01 represent signiﬁcant diﬀerences from control group.
development of diabetic cardiomyopathy. The up-regulation
in both MEK5 and ERK5 was signiﬁcantly decreased by
supplement garlic oil (10, 50 and 100mgkg−1 BW).
3.5. Pathologic Hypertrophy Marker ANP and BNP in the
Diabetic Rat Left Ventricle was Reduced by Garlic Oil
Supplement. To further understand whether the expression
of proteins associated with cardiac pathologic hypertrophy
was reduced by garlic oil treatment in the diabetic rat
hearts, the pathologic hypertrophy markers such as ANP
and BNP were analyzed by western blot (Figure 6). The
left ventricle obtained from the diabetic rat hearts showed
the signiﬁcant expression of ANP (Figure 6(a))a n dB N P
(Figure 6(b)); however, the up-regulation in ANP and BNP
in the hearts of diabetic rats was eﬃciently reduced by garlic
oil supplement (10, 50 and 100mgkg−1 BW). The results
suggested that garlic oil signiﬁcantly reduces the diabetes-
induced characteristics of cardiac pathologic hypertrophy,
improving the cardiac contractile function in the diabetic
rats (Figure 1 and Table 1).
4.Discussion
The major ﬁndings of the present study can be summarized
as follows: (i) STZ-induced diabetes leads to a decrease
in HR, cardiac contractile function, CO and contractile
velocity in the cardiac muscle. Interestingly, all of these
cardiac abnormalities induced by diabetes are improved
by garlic oil treatment. (ii) Diabetic cardiomyopathy is
structurally characterized by cardiac hypertrophy; in this
study, we further identify molecular mechanisms involved
in the diabetes-induced cardiac pathologic hypertrophy.
Cardiac hypertrophy-related MAPKs (e.g., p38, JNK and
ERK1/2) and IL-6/MEK5/ERK5 signaling pathways were
greatly activated, which resulted in the expression of patho-
logichypertrophy response markerssuchasANPandBNPin
the heart of diabetic rats. (iii) However, up-regulated activity
in MAPKs (p38, JNK and ERK1/2), IL-6/MEK5/ERK5 sig-
naling cascade and the expression of pathologic hypertrophy
markers (ANP and BNP) were signiﬁcantly inhibited when
supplyinggarlic oil(10,50and 100mgkg−1 BW). The results
suggest that garlic oilpossesses the potential cardioprotective
eﬀects for heart from diabetic cardiomyopathy (Figure 7).
Recent data from the Acute Decompensated Heart Fail-
ure National Registry demonstrates that ∼44% of patients
with decompensated heart failure suﬀer from DM [50].
Pathophysiology of DM includes hypoinsulinemia, hyper-
glycemia, cardiac hypertrophy and a cardiomyopathy that
is characterized by the presence of diastolic and/or systolic
contractile dysfunction. Prolonged cardiac hypertrophy has
been reported to be associated with the decompensation of
heart function, the development of heart failure and sudden
death in humans [12–14, 51]. Because of the side eﬀects of
Western drugs, a large number of studies have focused on
the eﬀects of natural products on cardiovascular protection.
Various oriental herb extracts or dietary supplement have
been adopted for preventing cardiovascular abnormalities or
disorders, for example, Li-Fu Formula for reducing cardiac
apoptosis [51]; Buyang Huanwu Decoction for protection
from ischemic heart disease [52]; fermented wheat germ8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Detection of pathologic hypertrophy marker (a) ANP and (b) BNP protein level from the left ventricles in control and diabetic
rats, analyzed by western blotting. GO-0, -10, -50 and -100 represent the doses of 0, 10, 50 and 100mg garlic oil per kg BW. Signal intensity
was quantitated using a PhosphoImager. Equal loading was assessed with an anti α-tubulin antibody. The average result ± SE of three
independent experiments is shown. ∗P<. 05, ∗∗P<. 01 represent signiﬁcant diﬀerences from control group.
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Figure 7: A schematic representation showing garlic oil ameliorates cardiac pathologic hypertrophy and subsequent cardiac dysfunction
in rats with diabetes by down-regulating the activities of MAPKs (p38, JNK and ERK1/2) and IL-6/MEK5/ERK5 signaling pathways.
Hyperglycemia greatly activates signaling pathways of MAPK (e.g., p38, JNK and ERK1/2) and IL-6/MEK5/ERK5, simultaneously, in the
hearts of diabetic rats. These activated signaling pathways signiﬁcantly induce the development of cardiac pathologic hypertrophy and the
expressions of pathologic hypertrophy response genes such as ANP and BNP. In diabetic rats, treatment involving garlic oil reduces the
hyperglycemia-cardiac pathologic hypertrophy and improves the heart function by eﬃciently de-activating MAPK (p38, JNK and ERK1/2)
and IL-6/MEK5/ERK5 signalingpathways.Evidence-Based Complementary and Alternative Medicine 9
extract (Avemar) for attenuating chronic hypertension, dia-
betes or metabolic syndrome-induced cardiovascular symp-
toms [53]; Tanshinone IIA for treatment of cardiovascular
disorders [54]; and garlic extract for improving cardiac
functions [55–57]. Garlic extract treatment shows some
beneﬁcial eﬀects on modulating the HR, rhythm and force
of cardiac contraction [55]. Garlic supplement signiﬁcantly
reduced HR during peak exercise and work load upon the
heart, resulting in better exercise tolerance in patients with
coronary artery disease [56, 58]. Garlic has a signiﬁcant
blood-pressure-lowering eﬀect by reducing the activity of
angiotensin-converting enzyme [57]a n dh a sp r o t e c t i v e
eﬀects on blocking hypoxic pulmonary hypertension in
vivo and attenuating age-related increases in aortic stiﬀness
[59]. In this study, we successfully used the STZ-induced
diabetic rats to mimic diabetic human with features of
cardiac dysfunction, for example, a decrease in FS and
EF [60], and an increase in LVESD [61]. STZ-induced
diabetes leads to a decrease in cardiac contractile function,
CO and contractile velocity in the cardiac muscle. In this
STZ-induced diabetic rat model, we observed that the up-
regulation of cardiac pathologic hypertrophy markers ANP
and BNP in the diabetic rat hearts was signiﬁcantly inhibited
bygarlicoilsupplement(10,50and100mgkg−1 BW). Garlic
oil supplement indeed improves HR, cardiac contractile
function, CO and contractile velocity in the diabetic rat
hearts. The results suggest that garlic oil improves cardiac
function of the diabetic rats by alleviating the development
of cardiac hypertrophy. In the clinical study, the evaluation
ofgarlic oil eﬀecton cardiac protection in diabetic patientsis
proceeding to conﬁrm the present study.
Evidences show that the stimulation of cardiomyocyte
hypertrophic growth like other environmental stresses such
as osmotic stress, DNA damage and ultraviolet radiation
results in the activation of protein kinase cascades, which in
turn activate MAPKs such as p38 MAPK, JNK and EKR1/2
[62]. These serine-threonine kinases have been shown to
phosphorylate the important downstream mediators that
participate in cellular regulations such as cell proliferation,
cell diﬀerentiation and cell growth process including cardiac
hypertrophy [20, 21, 23, 26, 28, 31, 32, 63]. In the present
study,wefoundthatincreased phosphorylation/activation of
p38, JNK and ERK1/2 was detected in the left ventricle of
the diabetic rat hearts. The ﬁndings suggest that increased
activity of MAPKssuch as p38, JNK and ERK1/2participates
in the cardiac pathologic hypertrophy in diabetic rat hearts.
Overexpressed IL-6 in the myocardium as a result of
AMI appears to play a central role in pathogenesis of
cardiac hypertrophy [33]. Activated MEK5/ERK5 signaling
pathway by IL-6 family cytokines has been reported to
lead to the eccentric cardiac hypertrophy that progresses to
dilated cardiomyopathy and sudden death [34, 64]. In the
present study, the left ventricles from diabetic rat hearts
showed a signiﬁcant up-regulation ofIL-6, MEK5andERK5,
suggestingthat activatedIL-6/MEK5/ERK5signaling cascade
participate in the diabetes-induced pathologic hypertrophy.
We further found that the activated MAPKs (e.g., p38, JNK
and ERK1/2) and IL-6/MEK5/ERK5 signaling pathway in
the diabetic rat hearts were signiﬁcantly inhibited when
applying garlic oil supplement. These ﬁndings suggest that
garlic oil improves heart function by greatly modifying the
intracardiac activity of MAPKs (e.g., p38, JNK and ERK1/2)
and IL-6/MEK5/ERK5 signaling pathways.
However, in the present study we also found that MEK5
protein in left ventricle was increased when STZ-induced
DM rats were treated with garlic oil (100mgkg−1 BW; GO-
100). We speculated that garlic oil treatment more than GO-
1 0 0d o s a g em a yi n i t i a t es o m es i d ee ﬀect in left ventricle.
Morefuturestudiesareneededtoinvestigatethesideeﬀectin
myocardial cells treated with over-dosage of garlic oil. In the
present study, we found that garlic oil treatment improves
heart function without signiﬁcant recovery from BW and
the level of blood glucose in STZ-induced DM rats. Besides
antioxidative [43, 65] and antiglycative [65]p r o p e r t i e s ,w e
speculatedthatsurvivalfactorsincardiaccellsofleftventricle
are up-regulated by garlic oil treatment to protect heart from
hyperglycemia-induced injury in STZ-induced DM rats. We
will further examine the eﬀect of garlic oil on expression of
survival factors in myocardial cells.
In conclusion, our ﬁndings show that garlic oil supple-
menttodiabeticheartsleadstoseveralalterationsatmultiple
levels, including the improvement of cardiac contractile
functions, the down-regulation of cardiac-hypertrophy-
related signaling activities and the decrease in expression
of cardiac pathologic hypertrophy response genes ANP and
BNP. Garlic oil indeed shows the cardioprotective potential
for heart from diabetic cardiomyopathy.
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